Pfizer (PFE) Advances Development of Danuglipron

Go back to Pfizer (PFE) Advances Development of Danuglipron

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

July 11, 2024 6:45 AM UTC

Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration enabling studies

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:... More